Protalix Biotherapeutics (PLX)

Protalix (PLX) Stock Price & Analysis


PLX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.94 - $2.21
Previous Close$2.03
Average Volume (3M)972.57K
Market Cap
Enterprise Value$127.78M
Total Cash (Recent Filing)$22.18M
Total Debt (Recent Filing)$33.47M
Price to Earnings (P/E)-6.6
May 10, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding50,665,598
10 Day Avg. Volume432,583
30 Day Avg. Volume972,571
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)-6.86
Price to Sales (P/S)2.03
Price to Cash Flow (P/CF)5.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda-11.85
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $0.94 and its highest was $2.21 in the past 12 months.
    What is Protalix Biotherapeutics’s market cap?
    Currently, no data Available
    When is Protalix Biotherapeutics’s upcoming earnings report date?
    Protalix Biotherapeutics’s upcoming earnings report date is May 10, 2023 which is in 51 days.
      How were Protalix Biotherapeutics’s earnings last quarter?
      Protalix Biotherapeutics released its earnings results on Feb 27, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.07.
        Is Protalix Biotherapeutics overvalued?
        According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Protalix Biotherapeutics pay dividends?
          Protalix Biotherapeutics does not currently pay dividends.
          What is Protalix Biotherapeutics’s EPS estimate?
          Protalix Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Protalix Biotherapeutics have?
          Protalix Biotherapeutics has 57,380,980 shares outstanding.
            What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
            Protalix Biotherapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 2.747%.
              Which hedge fund is a major shareholder of Protalix Biotherapeutics?
              Among the largest hedge funds holding Protalix Biotherapeutics’s share is Highbridge Capital Management LLC. It holds Protalix Biotherapeutics’s shares valued at 3M.


                Protalix Stock Smart Score

                The Protalix stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Protalix Biotherapeutics

                Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Collplant Holdings

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis